| 2021-09-06 |
温馨提示：
美股因劳工节，9月6日休市一天
|
| 2021-05-28 |
详情>>
股本变动：
变动后总股本4231.42万股
|
| 2021-05-28 |
详情>>
业绩披露：
2021年三季报(累计)每股收益1.36美元,归母净利润5765.00万美元,同比去年增长198.89%
|
| 2021-03-10 |
详情>>
业绩披露：
2021年中报每股收益0.87美元,归母净利润3653.20万美元,同比去年增长942.58%
|
| 2021-03-09 |
财报披露：
美东时间 2021-03-09 盘前发布财报
|
| 2020-12-10 |
详情>>
业绩披露：
2021年一季报每股收益0.58美元,归母净利润2446.40万美元,同比去年增长324.35%
|
| 2020-11-18 |
股东大会：
将于2020-12-16召开股东大会
会议内容 ▼▲
- 1.Elect as directors the ten (10) nominees named in the attached Proxy Statement (Proposal 1);
2.Conduct an advisory vote on the compensation of the Company’s Named Executive Officers (Proposal 2);
3.Consider and approve the Cantel Medical Corp. 2020 Equity Incentive Plan (Proposal 3);
4.Ratify the selection of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the fiscal year ending July 31, 2021 (Proposal 4);
5.Transact such other business as may properly be brought before the meeting.
|
| 2020-09-25 |
详情>>
业绩披露：
2020年年报每股收益0.32美元,归母净利润1370.70万美元,同比去年增长-75.07%
|
| 2020-09-25 |
详情>>
业绩披露：
2018年年报每股收益2.18美元,归母净利润9072.10万美元,同比去年增长27.87%
|
| 2020-06-09 |
详情>>
业绩披露：
2020年三季报(累计)每股收益0.46美元,归母净利润1928.80万美元,同比去年增长-58.22%
|
| 2020-03-20 |
复牌提示：
2020-03-19 10:27:27 停牌，复牌日期 2020-03-19 10:32:27
|
| 2020-03-06 |
详情>>
业绩披露：
2020年中报每股收益0.08美元,归母净利润350.40万美元,同比去年增长-90.78%
|
| 2020-03-06 |
详情>>
业绩披露：
2019年中报每股收益0.91美元,归母净利润3799.30万美元,同比去年增长-31.16%
|
| 2019-12-18 |
除权日：
美东时间 2020-01-16 每股派息0.11美元
|
| 2019-12-10 |
详情>>
业绩披露：
2020年一季报每股收益0.14美元,归母净利润576.50万美元,同比去年增长-69.99%
|
| 2019-11-15 |
股东大会：
将于2019-12-18召开股东大会
会议内容 ▼▲
- 1.Elect as directors the ten (10) nominees named in the attached Proxy Statement (Proposal 1);
2.Conduct an advisory vote on the compensation of the Company’s Named Executive Officers (Proposal 2);
3.Ratify the selection of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the fiscal year ending July 31, 2020 (Proposal 3);
4.Transact such other business as may properly be brought before the meeting.
|
| 2019-09-25 |
详情>>
业绩披露：
2019年年报每股收益1.32美元,归母净利润5499.10万美元,同比去年增长-39.38%
|
| 2019-06-26 |
除权日：
美东时间 2019-07-16 每股派息0.10美元
|
| 2019-06-06 |
详情>>
业绩披露：
2019年三季报(累计)每股收益1.11美元,归母净利润4616.60万美元,同比去年增长-37.51%
|
| 2018-12-19 |
除权日：
美东时间 2019-01-16 每股派息0.10美元
|
| 2018-11-15 |
股东大会：
将于2018-12-19召开股东大会
会议内容 ▼▲
- 1.Elect as directors the ten (10) nominees named in the attached Proxy Statement (Proposal 1);
2.Conduct an advisory vote on the compensation of the Company’s Named Executive Officers (Proposal 2);
3.Ratify the selection of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the fiscal year ending July 31, 2019 (Proposal 3);
4.Transact such other business as may properly be brought before the meeting.
|
| 2018-06-27 |
除权日：
美东时间 2018-07-16 每股派息0.09美元
|
| 2017-11-28 |
股东大会：
将于2018-01-03召开股东大会
会议内容 ▼▲
- 1.Elect as directors the ten (10) nominees named in the attached Proxy Statement (Proposal 1);
2.Conduct an advisory vote on the compensation of the Company’s Named Executive Officers (Proposal 2);
3.Conduct an advisory vote on the frequency of future advisory votes on the compensation of the Company’s Named Executive Officers (Proposal 3);
4.Consider and approve an amendment to the Company’s By-Laws to designate the Delaware Court of Chancery as the exclusive forum for certain legal actions (Proposal 4);
5.Ratify the selection of Deloitte & Touche LLP as our independent registered public accounting firm for the fiscal year ending July 31, 2018 (Proposal 5);
6.Transact such other business as may properly be brought before the meeting.
|
| 2017-11-01 |
除权日：
美东时间 2018-01-16 每股派息0.09美元
|
| 2017-06-29 |
除权日：
美东时间 2017-07-13 每股派息0.07美元
|
| 2016-11-28 |
股东大会：
将于2017-01-05召开股东大会
会议内容 ▼▲
- 1.Elect as directors the nine (9) nominees named in the attached Proxy Statement;
2.Conduct an advisory vote on the compensation of the Company's Named Executive Officers;
3.Ratify the selection of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending July 31, 2017;
4.Transact such other business as may properly be brought before the meeting.
|
| 2016-10-14 |
除权日：
美东时间 2017-01-12 每股派息0.07美元
|
| 2016-06-16 |
除权日：
美东时间 2016-07-13 每股派息0.06美元
|
| 2015-11-30 |
股东大会：
将于2016-01-07召开股东大会
会议内容 ▼▲
- 1.Elect as directors the nine (9) nominees named in the attached Proxy Statement (Proposal 1);
2.Consider and approve the Cantel Medical Corp. 2016 Equity Incentive Plan (Proposal 2);
3.Conduct an advisory vote on the compensation of the Company's Named Executive Officers (Proposal 3);
4.Ratify the selection of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending July 31, 2016 (Proposal 4);
5.Transact such other business as may properly be brought before the meeting.
|
| 2015-10-16 |
除权日：
美东时间 2016-01-13 每股派息0.06美元
|
| 2015-06-18 |
除权日：
美东时间 2015-07-15 每股派息0.05美元
|
| 2014-12-29 |
详情>>
内部人交易：
Krakauer Andrew A股份减少19140.00股
|
| 2014-11-26 |
股东大会：
将于2015-01-08召开股东大会
会议内容 ▼▲
- 1.Elect as directors the ten (10) nominees named in the attached Proxy Statement (Proposal 1);
2.Conduct an advisory vote on the compensation of the Company's Named Executive Officers (Proposal 2);
3.Ratify the selection of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending July 31, 2015 (Proposal 3);
4.Transact such other business as may properly be brought before
|
| 2014-11-07 |
除权日：
美东时间 2015-01-14 每股派息0.05美元
|
| 2014-06-19 |
除权日：
美东时间 2014-07-15 每股派息0.05美元
|
| 2013-12-02 |
股东大会：
将于2014-01-09召开股东大会
会议内容 ▼▲
- 1. Elect as directors the ten (10) nominees named in the attached Proxy Statement;
2. Conduct an advisory vote on the compensation of the Company's Named Executive Officers;
3. Ratify the selection of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending July 31, 2014;
4. Transact such other business as may properly be brought before the meeting.
|
| 2013-10-16 |
除权日：
美东时间 2014-01-15 每股派息0.05美元
|
| 2013-06-20 |
除权日：
美东时间 2013-07-19 每股派息0.04美元
|
| 2012-11-28 |
股东大会：
将于2013-01-11召开股东大会
会议内容 ▼▲
- 1.Elect as directors the ten (10) nominees named in the attached Proxy Statement
2.Approve an amendment to the Company's Certificate of Incorporation to increase the number of authorized shares of common stock from 30,000,000 to 75,000,000
3.Conduct an advisory vote on the compensation of the Company's Named Executive Officers
4.Ratify the selection of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending July 31, 2013
5.Transact such other business as may properly be brought before the meeting.
|
| 2012-11-01 |
除权日：
美东时间 2012-11-09 每股派息0.06美元
|
| 2012-06-15 |
除权日：
美东时间 2012-07-13 每股派息0.05美元
|
| 2011-10-21 |
除权日：
美东时间 2012-01-12 每股派息0.07美元
|
| 2011-06-17 |
除权日：
美东时间 2011-07-13 每股派息0.06美元
|
| 2010-10-21 |
除权日：
美东时间 2011-01-12 每股派息0.06美元
|
| 2010-06-09 |
除权日：
美东时间 2010-07-13 每股派息0.05美元
|